RSSS Q4 2026 Earnings Call Transcript

Research Solutions reported FY2026 revenue of $48.3 million, down 1.6% year over year, but net income more than doubled to $2.8 million and adjusted EBITDA reached a record $5.8 million as gross margin expanded 260bps to 51.9%. B2B ARR grew 14.1% to $16.2 million and AI-related ARR reached $800,000, up 125% sequentially, while platform revenue rose 9.8% to $20.8 million. Management expects further EBITDA and cash-flow growth in FY2027, supported by AI product adoption and B2B sales, though B2C is expected to remain flat and transaction revenue is expected to decline by a low single-digit percentage. The debt-free company ended the year with $12.6 million of cash and is evaluating acquisitions and potential share buybacks.

Analysis

RSSS is evolving into a higher-quality recurring-revenue asset, but the investable question is whether AI monetization offsets the cannibalization of legacy document-delivery demand quickly enough to re-rate the equity. The key positive is operating leverage: incremental B2B platform and agent-access revenue should carry very high contribution margins, so modest ARR acceleration can drive EBITDA faster than reported revenue. However, the disclosed AI ARR is not independently separated between new logos and renewal/upsell repricing, making it premature to capitalize the current run-rate as a standalone growth engine.

Near term, the stock can respond positively to buyback authorization or evidence that agentic products convert the pipeline into new enterprise logos rather than merely expanding existing contracts. Over the next 1-3 months, monitor first-quarter net B2B ARR, AI revenue disclosures, net retention, and transaction-revenue decline; these are more informative than gross AI query volume, which may rise without corresponding monetization. A low-float microcap structure also means any capital-return announcement can create a sharp technical move, but limited liquidity raises execution risk.

The contrarian concern is that management's connector strategy may reduce product control: researchers increasingly interact within OpenAI, Anthropic, and Microsoft interfaces, leaving RSSS vulnerable to platform partners commoditizing search and routing. RSSS's defensibility rests on rights-cleared access, publisher relationships, and citation-verification data—not generic AI distribution. The thesis fails if FY27 B2B ARR growth decelerates below low-double digits, AI bookings do not translate into recognized recurring revenue, or platform margins deteriorate as usage-based AI costs and publisher revenue shares scale.

No meaningful read-through exists for NFLX or NVDA; their inclusion is promotional rather than economically relevant. RSSS should be treated as a company-specific, liquidity-constrained special situation rather than an AI basket exposure.

Key Decisions for Investors

• Watch-list RSSS for a small long only after FY27 Q1 confirms B2B ARR growth of at least 12% and transaction declines remain no worse than mid-single digits. The setup is attractive if recurring growth and EBITDA expand together; avoid chasing a post-earnings liquidity-driven spike.
• Use a defined-risk position size given microcap liquidity: cap initial exposure at 25-50 bps of NAV, add only on verified AI revenue/new-logo disclosure, and exit if B2B ARR growth falls below 10% or management withdraws its expectation of EBITDA growth.
• Treat a formally authorized and executed buyback as a 1-3 month catalyst, not a structural thesis. Cash deployment is value-accretive only if repurchases occur below conservative recurring-revenue/EBITDA value; an acquisition would instead introduce integration and dilution risk.
• Do not express this through NVDA or broad AI software shorts. The relevant risk is enterprise-research workflow disintermediation by CHAT/Claude/Copilot, which is not cleanly hedgeable with the named large-cap tickers.